According to data released today, John Burbank (Trades, Portfolio), $3.4 billion global investment firm Passport Capital�� founder, introduced 58 new stocks into his portfolio in the fourth quarter, for a total of 141 positions. This portfolio is valued at $2.94 billion, having quarter-over-quarter turnover of 30%.
Passport�� investing strategy consists of a mix of macroeconomic analysis, fundamental research and quantitative tools.
The Largest New Buys
Gaming and Leisure Properties Inc. (GLPI)
Burbank purchased 2,213,948 shares of Gaming and Leisure Properties Inc. in a position absorbing 3.8% of the portfolio. The shares��price averaged $47 in quarter four.
Gaming and Leisure Properties spun off of Penn National Gaming Inc. on Nov. 1, 2013, and became the first gaming-focused real estate investment trust in January of this year. GLPI Inc. has a market cap of $3.46 billion; its shares were traded at around $38.80.
Top 5 Promising Stocks To Watch Right Now: Canadian Solar Inc.(CSIQ)
Canadian Solar Inc. engages in the design, development, manufacture, and sale of solar power products in Canada and internationally. The company offers solar cell and solar module products that convert sunlight into electricity for various uses. Its products include a range of standard solar modules for use in a range of residential, commercial, and industrial solar power generation systems. The company also designs and produces specialty solar modules and products consisting of customized modules that its customers incorporate into their products, such as solar-powered bus stop lighting; and specialty products, such as portable solar home systems and solar-powered car battery chargers. In addition, it sells solar system kits, a package consisting of solar modules produced by it and third party supplied components, such as inverters, racking system, and other accessories, as well as implements solar power development projects. The company sells its products under the Canad ian Solar brand name. Canadian Solar Inc. offers its standard solar modules through a direct sales force and sales agents primarily to distributors, system integrators, and original equipment manufacturer customers, as well as to solar projects; and specialty solar modules and products to the automotive, telecommunications, and light-emitting diode lighting sectors. The company was founded in 2001 and is based in Kitchener, Canada.
Advisors' Opinion:- [By Travis Hoium]
JinkoSolar (NYSE: JKS ) �and Canadian Solar (NASDAQ: CSIQ ) have slightly better balance sheets and they're focusing on expanding into systems, which will smooth out demand. JinkoSolar has a $1 billion financing deal with the China Development Bank to build projects, not just manufacturing capacity, which will help demand. Canadian Solar has built a huge systems business in Canada, including a $310 million, 130 MW project last month, and signed 18 MW of deals in South Carolina last week. The systems business generates stable demand and allows companies to compete more than on price alone, which helps margins.�
- [By Jake L'Ecuyer]
Leading and Lagging Sectors
In trading on Tuesday, technology shares were relative leaders, up on the day by about 0.12 percent. Leading the sector was strength from Aeroflex Holding (NYSE: ARX) and Canadian Solar (NASDAQ: CSIQ). Cyclical consumer goods & services shares declined around 0.71 percent in Tuesday's trading. - [By Michael Cintolo]
Canadian Solar (CSIQ) is a Chinese solar company that's headquartered in Ontario. The company makes silicon ingots, wafers, solar cells, and modules, and ranks among the largest solar companies in the world.
Top 5 Industrial Disributor Companies To Invest In 2014: MRG Metals Ltd (MRQ)
MRG Metals Limited is engaged in mineral exploration and production in Western Australia. The Company�� projects include the Xanadu gold project, the Mulgul copper prospect, the Braemore Battery prospect-Leonora, Diorite-Leonora and the Bellchambers. The Xanadu project consists of 14 prospecting license applications cover a total area of 26.7 square kilometers. The Mulgul exploration license application covers 336 square kilometers and is located 200 kilometers north of Meekatharra. The Company is acquiring nine granted prospecting licenses covering an area of 14.8 square kilometers, located five kilometers north of Leonora in the North-eastern Goldfields of Western Australia. Diorite is located 25 kilometers north of Leonora. There are three granted prospecting licenses covering an area of 5.42 square kilometers of greenstone lithologies. Effective June 28, 2013, MRG Metals Ltd (MRG) acquired Sasak Resources Australia Pty Ltd. Advisors' Opinion:- [By Magic Diligence]
Neustar's Lines of Business1) Numbering Services: 53% of total revenue, grew 7% in most recent quarter (mrq). These consist of databases that allow number portability - allowing customers to keep the same phone number even when changing cellular carriers or moving to a new address in the same area. Neustar is currently the sole provider of these services to the number portability administration center, or NPAC. We'll come back to this important fact later.
Top 5 Industrial Disributor Companies To Invest In 2014: Pharmacyclics Inc (PCYC)
Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.
As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.
Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).
PCI-27483 Factor VIIa Inhibitor
The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.
Factor VIIa PCI-27483 Clinical Development Update
A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.
A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.
Advisors' Opinion:- [By Keith Speights]
Last year, Pharmacyclics (NASDAQ: PCYC ) shares gained a whopping 280%. That was enough to land the biotech a spot on The Motley Fool's list of top health-care stocks in 2012. How is 2013 looking so far? Shares have gained more than 30% year to date but have been anemic since early March.
- [By Sean Williams]
Very few breakthrough therapies have been approved up to this point -- then again, we're only working with about 100 days for the Food and Drug Administration to have assigned such a designation. Vertex Pharmaceuticals'�received the first two "breakthrough therapy" designations from the FDA for two cystic fibrosis treatments, of which both involve the use of the already FDA-approved Kalydeco. The more intriguing "breakthrough therapy" designation is Pharmacyclics' (NASDAQ: PCYC ) Ibrutinib for the treatment of two rare blood cancers, which analysts feel could have a peak sales value of $5 billion if approved.
- [By Brian Orelli]
Imbruvica, which Johnson & Johnson developed with Pharmacyclics (NASDAQ: PCYC ) , is already approved in the U.S. to treat mantle cell lymphoma and chronic lymphocytic leukemia. The duo is also testing the drug in diffuse large B-cell lymphoma, multiple myeloma, follicular lymphoma, and Waldenstrom's macroglobulinemia.
- [By Sean Williams]
What's perhaps more remarkable is the fact that Pharmacyclics (NASDAQ: PCYC ) has three of those 23 approved breakthrough therapy designations for its lead experimental drug, ibrutinib. Ibrutinib, which is also licensed to Johnson & Johnson (NYSE: JNJ ) subsidiary Janssen Pharmaceuticals, was designated as a breakthrough therapy for patients with chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. The big potential indication here is CLL, which is the most common adulthood leukemia and occurs in 113,000 people in the U.S. By comparison, MCL diagnoses number about 5,000 each year.
Top 5 Industrial Disributor Companies To Invest In 2014: Rockwell Medical Technologies Inc.(RMTI)
Rockwell Medical Technologies, Inc. manufactures, sells, and distributes hemodialysis concentrate solutions and dialysis kits primarily in the United States, Latin America, Asia, and Europe. The company?s hemodialysis product duplicates kidney function in patients with failing kidneys, known as end stage renal disease, an advanced stage of chronic kidney disease; and dialysis solutions are used to maintain life, remove toxins, and replace nutrients in the dialysis patient?s bloodstream. Its products include Renal Pure and CitraPure liquid acid concentrate, Dri-Sate dry acid concentrate and mixing systems, RenalPure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrates; and various ancillary products comprising blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies. The company also has a license to manufacture and sell soluble ferric pyrophosphate (SFP), a Phase III clinical trial p roduct to improve the treatment of dialysis patients with iron deficiency. Rockwell Medical Technologies sells its products to domestic hemodialysis providers through direct sales people and independent sales representation companies, as well as through independent sales agents and distributors internationally. The company was founded in 1995 and is based in Wixom, Michigan.
Advisors' Opinion:- [By Roberto Pedone]
Rockwell Medical (RMTI) manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the U.S. and internationally. This stock closed up 5.3% to $5.17 in Tuesday's trading session.
Tuesday's Range: $4.89-$5.25
52-Week Range: $3.16-$8.59
Tuesday's Volume: 1.15 million
Three-Month Average Volume: 1.26 millionFrom a technical perspective, RMTI bounced sharply higher here right above some near-term support levels at $4.81 to $4.65 with decent upside volume. This move is quickly pushing shares of RMTI within range of triggering a major breakout trade. That trade will hit if RMTI manages to take out its 200-day moving average at $5.24 and then once it clears more near-term resistance at $5.94 with high volume.
Traders should now look for long-biased trades in RMTI as long as it's trending above some key near-term support levels at $4.81 to $4.65 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.26 million shares. If that breakout triggers soon, then RMTI will set up to re-test or possibly take out its next major overhead resistance levels at $8 to $8.50.
- [By Jake L'Ecuyer]
Rockwell Medical (NASDAQ: RMTI) was also down, falling 19.90 percent to $10.80 after Brean Capital initiated the company at a Sell rating and a $4 price target.
No comments:
Post a Comment